+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics



Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics



Medical Science Monitor 8(3): Br100-4



Bacteria of the Klebsiella genus may cause numerous infections in human, which are often treated with beta-lactam antibiotics. The fundamental mechanism of Klebsiella resistance to penicillins or cephalosporins involves the production of enzymes--extended-spectrum beta-lactamases (ESBLs). Because of resistance of many Klebsiella spp. strains to beta-lactams, alternative antibiotic therapy can make use of aminoglycosides and quinolones. The study analyzed the prevalence of ESBL -type enzymes among 256 Klebsiella pneumoniae strains isolated from various clinical materials collected from patients hospitalized between 1997 and 2000. ESBLs were detected by double-disk synergy test (DDST). The prevalence of strains resistant to selected aminoglycosides (gentamicin, amikacin, netilmicin) and quinolones (ciprofloxacin, norfloxacin, nalidixic acid) in the particular years was analyzed. Drug sensitivity was determined by disk-diffusion method according to the recommendations of the National Reference Center for Microbial Drug Sensitivity. During the analyzed time interval, a significant increase of the number of K. pneumoniae ESBL(+) strains was noted: in 1997 - 16.5% (14/85) and in 2000 - 40.4% (22/54) (p<0.001). Among the ESBL(+) strains, an increase of the number of strains resistant to the tested antibiotics, except for nalidixic acid, was demonstrated A statistically significant increase of multidrug-resistant K. pneumoniae strains, including strains producing ESBLs, was demonstrated in the analyzed material.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047247829

Download citation: RISBibTeXText

PMID: 11889457


Related references

Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. American Journal of Clinical Pathology 120(2): 265-267, 2003

Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. Journal of Clinical Microbiology 42(1): 269-275, 2004

Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes. Infection Control and Hospital Epidemiology 29(11): 1026-1034, 2008

Antimicrobial activity of antibiotics in combination with natural flavonoids against clinical extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae. PhytoTherapy Research 19(7): 612-617, 2005

Cefotetan -cloxacillin synergy test for differentiation of Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase from strains producing extended-spectrum beta-lactamases and deficient in porins. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 43: 168, 2003

Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli versus Klebsiella pneumoniae: Does type of germ really matter?. Infection Control and Hospital Epidemiology 39(9): 1137-1138, 2018

High frequency of beta-lactam susceptibility in CTX-M-type extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. Journal of Antimicrobial ChemoTherapy 65(11): 2481-2483, 2010

In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagnostic Microbiology and Infectious Disease 49(1): 41-46, 2004

Transferable resistance to 3rd generation cephalosporins and aztreonam in strains of Klebsiella pneumoniae producing beta-lactamases with an extended spectrum (ESBL). Epidemiologie Mikrobiologie Imunologie 48(1): 21-27, 1999

Extended-spectrum beta-lactamase (ESBL) CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae in Sofia, Bulgaria. Clinical Microbiology and Infection 10(8): 752-755, 2004

Extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae: activity of single versus combination agents. Journal of Antimicrobial ChemoTherapy 51(3): 737-739, 2003

Extended spectrum beta lactamase (ESBL) producing Escherichia coli and klebsiella pneumoniae in diabetic foot infection. Indian Journal of Medical Microbiology 26(3): 281-282, 2008

Clonal dissemination of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae isolates in a Korean hospital. Journal of Korean Medical Science 23(1): 53-60, 2008

Antimicrobial Susceptibility of Klebsiella pneumoniae Producing Extended-Spectrum beta-lactamase (ESBL) Isolated in Hospitals in Brazil. Brazilian Journal of Infectious Diseases 1(4): 196-203, 1997

Extended-Spectrum beta-lactamase (ESBL) producing Enterobacter aerogenes phenotypically misidentified as Klebsiella pneumoniae or K. terrigena. Bmc Microbiology 4: 49, 2004